PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
January 30, 2025Expert Opinion on Drug Safety

Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database

View Full Paper
Ask AI
Bookmark
Share

Why the study?

While VEGFR-TKIs are known to cause adverse events like cardiotoxicity and haematotoxicity, their impact on liver injury remains understudied.

Are VEGFR-TKIs associated with liver injury in patients reported in the FAERS database?

Population

FAERS database reports from 2006 to 2024

Comparison

Nine VEGFR-TKIs (Axitinib, Vandetanib, Cabozantinib, Lenvatinib, Pazopanib, Ponatinib, Regorafenib, Sunitinib, Sorafenib)

Design

Pharmacovigilance disproportionality and Bayesian analysis

Authors

XWXiang WangRCRujie ChenJLJialin Liu

Discussion

Loading...

Member takes

Overview

FAERS signals link VEGFR-TKIs to liver injury; leaves open causality and optimal monitoring in prospective studies.

Structured PICO

Are VEGFR-TKIs associated with liver injury in patients reported in the FAERS database?

P
Population
Cases from the USA FDA Adverse Event Reporting System (FAERS) database from 2006 to 2024
I
Intervention
Nine vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR-TKIs): Axitinib, Vandetanib, Cabozantinib, Lenvatinib, Pazopanib, Ponatinib, Regorafenib, Sunitinib, Sorafenib
O
Outcome
Liver injury (including onset time, mortality, and hospitalization rates)safety

VEGFR-TKIs are associated with significant liver injury, highlighting the need for close monitoring to mitigate risks of hospitalization and early mortality.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6a1e77798a8a69122355e874https://doi.org/10.1080/14740338.2025.2460449
View Full Paper
Ask AI
Bookmark
Share